Chronic Heartburn And Acid Reflux Treatment In Clearwater

Most people with GERD do not overproduce acid. The reflux barrier has failed mechanically. The lower esophageal sphincter has weakened, the diaphragm no longer supports it from the outside, and nearly every reflux patient has a hiatal hernia, even when it is small enough to be missed on endoscopy.

Proton pump inhibitors such as omeprazole and pantoprazole suppress acid production for roughly 12 to 16 hours a day. H2 blockers like famotidine last about 4 to 6 hours and take around 30 minutes to start working, which makes them useful as needed rather than as a foundation. Neither one strengthens the sphincter. Neither one repairs a hernia. Reflux events continue at the same rate, and what comes up still contains bile, pepsin and trypsin.

That is the mechanism behind the pattern most patients describe. The medication helped at first. Symptoms crept back. The dose went up. A second drug got added.

One newer option that local GERD pages have not caught up to is vonoprazan (Voquezna), which is a potassium-competitive acid blocker rather than a PPI. The FDA approved it in November 2023 for healing all grades of erosive esophagitis and in July 2024 for heartburn relief in non-erosive GERD. It is taken once daily, and per the FDA prescribing information it does not carry the meal-timing rules PPIs require. Two caveats belong with that. The Medical Letter’s independent review concluded that other acid-suppressing drugs remain preferable until longer-term safety data arrive. And a stronger acid blocker is still an acid blocker. It changes what your reflux is made of, not whether reflux happens.

Get evaluated by a foregut specialist if any of these apply: a hiatal hernia larger than 3 centimeters, symptoms that persist on a daily PPI, a need for twice-daily dosing or drug combinations to stay comfortable, severe esophagitis or Barrett’s esophagus or a peptic stricture, or a decision that you do not want to take acid suppression for the rest of your life.

An upper endoscopy does not diagnose GERD. It looks for damage reflux has already caused: esophagitis, Barrett’s esophagus, ulcers, strictures. It does not measure whether reflux is happening, how often, or why. Plenty of patients with significant reflux have a completely normal endoscopy, particularly while taking acid suppression. Small hiatal hernias are not visible on every scope either.

Each test answers a different question.

• Upper endoscopy shows anatomy and complications, and allows a pH probe to be placed.
• Esophageal pH monitoring is the gold standard for diagnosing GERD. Data records over 48 to 72 hours through a wireless Bravo capsule or a catheter while you eat, sleep, work and exercise normally. It captures how often reflux happens, how long each episode lasts, when it happens, and whether your symptoms line up with actual reflux events.
• Esophageal manometry measures the strength and coordination of your esophagus. This is what determines whether a full or partial wrap is safe, whether a magnetic device is appropriate, or whether surgery should be avoided entirely. Skipping it is the single most predictable cause of swallowing problems after reflux surgery.
• Barium swallow shows how the esophagus behaves while you actually swallow, and it is used selectively. One reason it earns its place: patients correctly identify where food is sticking only about 60 percent of the time. Someone who feels food catching in the throat is often, on imaging, having delay in the lower esophagus.

If your symptoms are throat clearing, hoarseness, chronic cough or a lump-in-the-throat sensation rather than heartburn, standard reflux testing can miss the problem completely. Most pH studies measure only above the lower esophageal sphincter. Dr. Grandhige uses a customized 24-hour dual-channel pH impedance probe that also measures above the upper esophageal sphincter, and the impedance channel detects non-acid reflux that pH testing alone cannot see. The reason this matters is sensitivity: the esophagus may tolerate 40 to 50 reflux episodes a day, while the larynx and pharynx can produce symptoms from one.

That difference changes who gets operated on. Patients evaluated for silent reflux (LPR) with standard testing are commonly quoted around a 50 percent chance that surgery helps. With dual-channel testing used to select candidates, Dr. Grandhige’s reported improvement rate is approximately 80 percent, and only about 50 to 60 percent of LPR patients have testing that supports an operation at all. Fewer surgeries, on better-selected patients.

Gopal Grandhige, MD is a board-certified general surgeon who has focused on foregut surgery since 2009, which is over 16 years in the Tampa Bay area. He founded Tampa Bay Reflux Center in 2009 and Tampa Bay Reflux Institute in 2022.

His training: biology at Johns Hopkins University, medical degree at the University of Michigan, general surgery residency at Yale-New Haven Hospital, then two fellowships there, one in burn and critical care and one in foregut and minimally invasive surgery. He is a Fellow of the American College of Surgeons, a member of SAGES, and a founding member of the American Foregut Society.

The practice covers benign disease of the esophagus, diaphragm and stomach only. That includes GERD, hiatal hernias, silent reflux, achalasia treated with Heller myotomy, and gastroparesis treated with endoscopic pyloromyotomy. He does not treat esophageal or gastric cancer. He also does not operate on patients whose symptoms are unlikely to improve with surgery, and esophageal hypersensitivity and functional chest pain both mimic reflux without being surgically correctable.

You can check his license status and disciplinary history yourself through the Florida Department of Health license verification portal, and his board certification through the American Board of Surgery and the American College of Surgeons directories.